In the fifth event of our Psychedelic Revival series, we’ll explore the post-legalization landscape, what we anticipate psychedelic therapy will look like, insurance structures, clinical models, and how the field of mental health might change. We’ll also explore the topics of legalization, decriminalization, and the FDA approval process.
Featured speakers for the event included:
Stephen Ross, MD
Dr. Stephen Ross, a University of Pennsylvania alumnus, is a Research Associate Professor in the Departments of Psychiatry and Child and Adolescent Psychiatry at NYU Grossman School of Medicine. Dr. Ross is a founding member of the NYU Psychedelic Research Group and is currently associate director of NYU Langone’s Center for Psychedelic Medicine and director of the Psychedelic Medicine Research Training Program. Dr. Ross’s main research interests focus on developing novel pharmacologic-psychosocial approaches to treating addictive disorders, including the intersection between pain and addiction; psychiatric and existential distress associated with advanced or terminal cancer; major depression; PTSD; and personality disorders.
Scott Shannon, MD
Scott Shannon, MD, has been a student of consciousness since his honor’s thesis on that topic at the University of Arizona in the 1970s. Following medical school, MDMA assisted psychotherapy became part of his practice before this medicine was scheduled in 1985. Scott has published four books on holistic and integrative mental health. Scott is a past President of two national medical organizations and currently teaches ketamine-assisted psychotherapy widely. He serves as a site Principal Investigator and therapist for the Phase III trial of MDMA assisted psychotherapy for PTSD sponsored by MAPS at the Wholeness site in Fort Collins.
Rachel Yehuda, PhD
Rachel Yehuda, PhD, Professor of Psychiatry and Neuroscience, is the director of the Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai, the Vice Chair for Veterans Affairs in the Psychiatry Department, and the Director of the Traumatic Stress Studies Division at the Mount Sinai School of Medicine. She also leads the PTSD clinical research program at the Neurochemistry and Neuroendocrinology laboratory at the James J. Peters VA Medical Center. Dr. Yehuda is a recognized leader in the field of traumatic stress and has authored more than 500 published papers, chapters, and books in the field of traumatic stress and the neurobiology of PTSD. Her research has focused on PTSD in combat veterans, the children of Holocaust survivors and the children of pregnant women who survived the 9/11 attacks.
8 сен 2024
